Skip to content

CG Oncology CGON Net Change in Cash

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Gilead Sciences logo
Gilead SciencesGILD
$65M+103%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$117.04M+241%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$70.8M-354%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$45.12M+507%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's net change in cash?
CG Oncology (CGON) reported net change in cash of $1.21M in Q1 2026.
How has CG Oncology's net change in cash changed year-over-year?
CG Oncology's net change in cash increased by 100.6% year-over-year, from -$215.6M to $1.21M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.